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Abstract. In cancer therapy and imaging, the systemic passive delivery of particulate systems has relied
on the enhanced permeability and retention (EPR) effect: sufficiently small particles can cross the
endothelial fenestrations and accumulate in the tumor parenchyma. The vast majority of man-made
particulates exhibit a spherical shape as a result of surface energy minimization during their synthesis.
The advent of phage display libraries, which are revealing the extraordinary molecular diversity of
endothelial cells, and the development of processes for fabricating particles with shapes other than
spherical are opening the path to new design solutions for systemically administered targeted
particulates. In this paper, the role of particle geometry (i.e., size and shape) is discussed at the tissue
and cellular scales. Emphasis is placed on how the synergistic effect of particle geometry and molecular
targeting can enhance the specificity of delivery. The intravascular delivery process has been broken into
three events: margination, firm adhesion and control of internalization. Predictions from mathematical
models and observations from in-vitro experiments were used to show the relevance of particle geometry
in systemic delivery. Rational design of particulate systems should consider, beside the physico-chemical
properties of the surface coatings, geometrical features as size and shape. The integration of
mathematical modeling with in-vitro and in-vivo testing provides the tools for establishing a rational
design of nanoparticles.
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INTRODUCTION
Organic, inorganic and biological particulate systems are
being developed by several laboratories for different biomedical
applications ranging from early disease detection to imaging,
therapy and follow-up (1–3). Particulate systems are sufficiently
small to be administered at the systemic level and transported
by the blood flow along the circulatory system can reach
potentially any tissue and organ (biological target) within the
host. Differently from freely administered drug molecules and
monoclonal antibodies, particles can be engineered to carry a
large number of drug molecules and contrast agents providing
simultaneously a therapeutic and imaging function (particle
multi-functionality). Moreover, the particle surface can be
conjugated with several antibodies and ligand molecules to
enhance the specific recognition of the biological target
through the formation of ligand-receptor bonds, as well as
polymer chains of different length and type to effectively
“camouflage” the particle from the reticular-endothelial system
(RES) sequestration (Fig. 1).
So far, the main strategy followed for the delivery of
particulate systems has relied on exploiting the well known
enhanced retention and permeability (EPR) effect, in which
sufficiently small particles can passively cross the tumor
endothelial barrier through fenestrations with a characteristic
size of the order of few hundreds of nanometers. This strategy
poses a limit to the maximum size of the particles to about
100–300 nm, because larger particles would be less likely to
pass through the fenestrations passively. Moreover, such an
approach relies exclusively on the presence of vascular
fenestrations whose size is known to change over time, being
negligibly small at an early stage of the disease; to be affected
by the type of tumor and site of tumor growth (4); and to be
potentially reduced by anti-angiogenic therapies.
Recent studies are confirming that biological and bio-
physical differences exist between normal and abnormal
endothelium, for cancer as well as for other diseases. Differ-
ences have been observed in the organization of the vascular
network and mean blood velocity (5); and in the expression
of specific markers whose surface density can be much higher
on the abnormal compared to the regular endothelial cells
(6). Phage display libraries are currently being used to map
235 0724-8741/09/0100-235/0 # 2008 Springer Science + Business Media, LLC
Pharmaceutical Research, Vol. 26, No. 1, January 2009 (# 2008)
DOI: 10.1007/s11095-008-9697-x
1 School of Health Information Sciences, The University of Texas
Health Science Center, Houston, Texas 77030, USA.
2 The Brown Foundation Institute of Molecular Medicine, The
University of Texas Health Science Center, Houston, Texas 77030,
USA.
3Department of Genitourinary Medical Oncology and Department of
Cancer Biology, The University of Texas M. D. Anderson Cancer
Center, Houston, Texas 77030, USA.
4 BioNEM-Center of Bio-/Nanotechnology and -/Engineering for
Medicine, University of Magna Graecia, 88100, Catanzaro, Italy.
5 Department of Experimental Therapeutic and Rice University,
Department of Biomedical Engineering, The University of Texas
M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
6 To whom correspondence should be addressed. (e-mail: Paolo.
Decuzzi@uth.tmc.edu)
the endothelial surface in-vivo targeting specific vascular
markers for different diseases (7). Such experimental evi-
dence has encouraged the definition of an alternative delivery
strategy which aims at exploiting vascular biodiversity to
optimally design particulate systems able to recognize the
abnormal endothelium and adhere firmly to it under flow.
From this privileged position, the vascular target particle (first
stage) can release towards the extravascular space smaller
nanoparticles (second or multiple stages) that can be loaded
with therapeutic and imaging agents (8). This approach,
known as vascular targeting, has two main advantages
compared to the EPR based strategies: (1) can be employed
for any pathology involving the endothelium, without requir-
ing any alteration in the blood vessel permeability; (2) large
particles with much higher payloads can be used.
The archetypal form of particulate systems for systemic
drug delivery is the liposome, a system composed by a
phospholipid and cholesterol bilayer with an aqueous inner
core, which assumes a classical spherical shape according to
surface energy minimization. However, striking new develop-
ments in polymer science and in micro/nano fabrication have
led to the synthesis and fabrication of particulate systems with
a broad spectrum of shapes. By particulate systems all the
particles with a micrometer characteristic size are identified.
For instance, we have demonstrated how to fabricate silicon
particles with a quasi-hemispherical shape (9,10); targeted
networks of gold nanoparticles and bacteriophage have been
developed by the group of Pasqualini and Arap (11); Illing et
al. (12) have presented solid lipid nanoparticles with an
anisometric shape; van Dillen et al. (13) have used ion beam
radiation to transform spherical silica particles into oblate
ellipsoids; Kohli and Martin (14) have presented cylindrical
smart nanotubes for biotechnological applications; Subrama-
niam et al. (15) demonstrated that gas bubbles and liquid
drops can exist in a stable non-spherical shapes; DeSimone’s
group (2) has developed the PRINT technology (Particle
Replication In Non-wetting Templates) for the direct fabri-
cation of shape-specific polymer nanoparticles; and more
recently Mitragotri and his colleagues (16) have demonstrat-
ed polymeric micro- and nano-particles of complex shapes.
The above list just gives a glimpse of the variety of shapes and
materials used to fabricate new particulate systems in which
at least one geometrical feature is sub-micrometer in size.
The shift of the EPR paradigm, which has been limiting
particle size in cancer therapy and imaging, in favor of the
more general vascular targeting approach and the develop-
ment of processes for fabricating particles with shapes other
than spherical are opening the path to new, and hopefully
revolutionary, design solutions where particulate systems with
sizes ranging from few tens of nanometers up to few microns,
and with diverse shapes, as discoidal, spheroidal, cylindrical
and conical, are being employed. There is no doubt that this
advance would widen the spectrum of solutions by just adding
extra degrees of freedom to the problem (i.e., size and shape),
but some central questions remain: Does particle geometry
really matter in systemic drug delivery? Is it equally relevant
at each different length scales involved in systemic drug
delivery: vascular and cellular, and sub-cellular level? The
motivation for this manuscript originates from these open
questions.
Interestingly, within the engineering and physical com-
munity, size and shape have been known for a long time to
‘matter’ even at the micro- and nano-scales. For instance,
Albert Einstein (17) in 1911 showed how the coefficient of
molecular diffusion D of a passive suspension of particles
grows with the inverse of the particle radius a. George Jeffery
(18) in 1922, studied the motion of ellipsoidal particles in
viscous flows demonstrating the effect of particle shape on the
rheology of the suspension. More recently, Han et al. (19)
have analyzed experimentally and theoretically the Brownian
motion of an ellipsoidal particle showing how D as well as the
particle trajectory are influenced by size and aspect ratio
(shape). Moving to adhesive interactions, which dominate the
micro- and nano-world, nature has donated to insects and
lizard the ability of clinging vertical walls and even ceilings
and being able to hold their own weight when adhering to the
ceiling. A striking example is given by the geckos, whose feet
are made up by a huge number of fine fibers with a terminal
size of few hundreds of nanometers and with a spatula-like
shape. It has been confirmed theoretically (20,21) that, even
at sub-micrometric scales, the shape of two interacting bodies
can dramatically affect the interfacial adhesive interactions.
VASCULAR DIVERSITY AND PHAGE DISPLAY
LIBRARIES
The search for molecular targets in proliferating vascu-
lature represents a challenge. The need for such differential-
ly-expressed endothelial cell surface markers is clear, as they
are likely to play a regulatory role in angiogenesis and tumor
progression. Probing molecular diversity at the cellular level
is also required for the development of targeted therapies. In
vivo screenings based on intravenous administration of
combinatorial libraries often results in multiple targeting
ligands that recognize markers expressed within selective
vascular beds. By using this approach, one can dissect
vascular heterogeneity within healthy or diseased tissues.
Fig. 1. A particulate system: therapeutic and contrast agents (red) are
loaded within the core of the particle; the surface is decorated with
ligand molecules (green) and polymer chains (violet) for RES
camouflage.
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Targeting and characterization of the receptors recognized by
homing peptides has brought functional insights in vascular
biology. Strategies for targeted tissue ablation have also been
developed based on this approach, and utilized successfully in
pre-clinical models (7).
Filamentous phage (f1, fd, and M13) are single-stranded
DNA viruses that have nanometer dimensions. The major
coat proteins (pIII and pVIII) expressed on the surface can
be genetically manipulated to externally display small pep-
tides in combinatorial libraries. The potential range of
applications for this technique is quite broad, and the past
decade has seen considerable progress in the construction of
phage-displayed peptide libraries and in the development of
screening methods in which the libraries are used to isolate
peptide ligands. For example, the use of peptide libraries has
made it possible to characterize interacting sites and receptor-
ligand binding motifs within many proteins, such as anti-
bodies involved in inflammatory reactions or integrins that
mediate cellular adherence. This methodology has also been
used to identify novel peptide ligands that serve as leads for
the development of peptidomimetic drugs or imaging agents.
In addition to peptides, larger protein domains such as single-
chain antibodies can also be displayed on the phage surface.
Briefly, filamentous phage are propagated in pilus-positive
bacteria that are not lysed by the phage but rather secrete
multiple copies of phage that display a particular insert.
Phage that bind to a target molecule can be eluted and then
amplified in a host bacteria. Multiple rounds of biopanning
leads to a population of selective targeting peptides. The
amino acid sequence of the recovered peptides is determined
by sequencing the DNA corresponding to the peptide insert
in the phage genome. Sequences are analyzed to monitor
enriched motifs compared to the unselected library and are
used to identify proteins, or ligands, with which the motifs
share sequence homology, and cross-referenced with data
from proteomic or microarray studies for selectivity. Once a
candidate target is identified as the receptor of a homing
peptide, it can be isolated, purified and cloned by using
standard biochemical methods such as affinity-chromatogra-
phy or genetic methods such as expression cloning.
By applying in vivo selection of peptides from phage-
display peptide libraries, peptides that selectively target
normal organs in mice and in patients have identified; so
far, brain, kidney, adipose, lung, skin, pancreas, retina,
intestine, uterus, prostate, and adrenal gland have been
targeted. These results indicate that the vascular endothelium
of normal organs is modified in ways that allow differential
targeting with peptide probes. Means of identifying peptides
that home to the angiogenic vasculature of tumors have been
also devised. Moreover, we have assembled a panel of peptide
motifs that target the blood vessels of tumor xenografts. The
RGD-4C peptide has previously been identified as selectively
binding αv integrins and is now among the most studied tumor
homing peptides (Table I). These tumor-targeted peptides
have been shown to be more effective and less toxic than
parental compounds in experimental models when coupled to
cytotoxic drugs or proapoptotic peptides.
SIZE AND SHAPE EFFECTS IN SYSTEMIC DELIVERY
OF PARTICULATE SYSTEMS
In the more general vascular targeting approach, particles
are transported by the blood flow and interact specifically
(formation of ligand-receptor bonds) and non-specifically
(van der Waals, electrostatic and steric interactions) with the
blood vessel walls, seeking for the diseased endothelium
(vascular target). Once suitable conditions are met, in terms
of expression of vascular receptors and hydrodynamic shear
stresses at the wall, particles adhere firmly to the blood vessel
walls and are then required to control cell uptake, avoiding or
favoring it depending on their final objective. Based on this
description, the intravascular “journey” of the particle can be
broken down into three events, namely: the margination
dynamics, the firm adhesion and the control of internaliza-
tion. The role played by particle geometry (size and shape) in
each of these events is discussed.
To be effective—regardless of the strategy considered—
intravascularly administered particles must avoid recognition
and sequestration by the reticulo-endothelial system (RES), a
complex system of phagocytic cells lining the sinusoids of the
liver; accumulating in the red pulp of the spleen, bone
marrow and lymph nodes. Particle size has been shown to
have a dramatic effect on RES sequestration: particles of
10 μm and more have been shown to cause embolization in
the liver and lungs (22); whereas 3–4 μm particles have been
shown to accuulate permanently into the open circulation of
Table I. Cell Surface Receptors and Homing Motifs Isolated by In Vivo Phage Display
Receptor Function/class Carrier Localization Homing motif
αv integrins Cell adhesion Yes EC, tumor cells RGD-4C
Aminopeptidase N Protease Yes EC, pericytes, tumor cells CNGRC
Aminopeptidase A Protease N/D Pericytes CPRECES
NG2 Proteoglycan N/D Pericytes, tumor cells GSL
MMP-2/MMP-9 Protease Yes EC, tumor cells CTTHWGFTLC
MDP Protease N/D EC CGFEC
Prohibitin Chaperone/Cell growth/Survival Yes EC CKGGRAKDC
FcRn/beta(2)m Immunoglobulin transporter N/D Trophoblasts TPKTSVT
IL-11R Cytokine receptor Yes EC, tumor cells CGRRAGGSC
MMP matrix metalloproteinase, EC endothelial cells, N/D not determined, R arginine, G glycine, C cysteine, D aspartic acid, E glutamic acid,
V valine, A alanine, K lysine, N asparagine, P proline, S serine, L leucine, T threonine, H histidine, W tryptophan, F phenylalanine, MDP
membrane dipeptidase
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the spleen (23). For sub-micrometer particles, a classical
strategy to increase the circulation half-time and escape the
RES recognition consists in decorating the particles with
polymer chains (PEG) (24).
Margination Dynamics
Margination is a well-known term in physiology conven-
tionally used to describe the lateral drift of leukocytes and
platelets from the core blood vessel towards the endothelial
walls. Similarly a marginating particle is a particle designed to
move preferentially in close proximity to the blood vessel
walls, and margination dynamics is the process of lateral
drifting of the particle from the blood vessel core to the walls.
Accumulating the particles in close proximity to the blood
vessel walls is highly desirable in vascular targeting, as well as
in passive EPR approach, for two main reasons: (1) particles
can ‘sense’ the vessel walls for biological and biophysical
diversities, as for instance the over expression of specific
vascular markers or the presence of sufficiently large
fenestrations through which extravasate; (2) particles can
more easily leave the larger blood vessels in favor of the
smaller, accumulating in a larger number within the micro-
circulation (Fig. 2). Whilst leukocyte and platelets margin-
ation is an active process requiring an interaction with red
blood cells and the dilatation of inflamed vessels with blood
flow reduction (25); particle margination can only be
achieved by proper rational design.
Red blood cells (RBCs) have a behavior opposite to
margination, with cells accumulating preferentially within the
core of the vessels avoiding any interaction with the walls and
staying in a larger portion in the macro-circulation (40–45%
in volume) compared to the micro-circulation (20–25% in
volume). The core accumulation of RBCs has long been
described by Fahraeus and Lindqvist (26) and is referred to as
the plasma skimming effect. An immediate consequence of
this phenomenon is the formation of a ‘cell free layer’ in
proximity of the wall, whose thickness varies with the size of
the channel and mean blood velocity, being as large as few
tens of microns in arterioles (100 and more μm in diameter)
and few microns in capillaries [ten and more μm in diameter
(27)]. Particles designed to marginate would then tend to
accumulate in the cell free layer where an almost linear
laminar flow is observed. The motion of spherical particles in
a linear laminar flow has been described by Goldmann et al.
(28) who showed how the exerted hydrodynamic forces grow
with the particle radius and that no lateral drift would be
observed unless an external force is applied, as gravitational
or magnetic, or short ranged van der Walls and electrostatic
interactions (29). In other words, a neutrally buoyant
spherical particle moving in proximity to a wall can drift
laterally only if an external force is applied forcing the
particle to do so. It is here important to recall that
gravitational force has been shown to be relevant even for
sub-micrometer polystyrene beads (relative density to water
of 0.05 g/cm3), and that margination dynamics can be
effectively controlled in horizontal channels by changing the
size of non-buoyant nanoparticles (30).
Non-spherical particles exhibit more complex motions
with tumbling and rolling which can be exploited to controll
their margination dynamics without any need for lateral
external forces. The longitudinal (drag) and lateral (lift)
forces as well as the torque exerted by the flowing blood
depend on the size, shape and orientation of the particle to
the stream direction and changes over time as the particle is
transported (Fig. 3). For non spherical particles, it has been
shown that the lateral drifting velocity is directly related to
their aspect ratio (31,32), with a maximum between the two
extremes: sphere, with aspect ratio unity, and disk, with
aspect ratio infinity. Figure 4 shows the trajectories of a
neutrally buoyant spherical and ellipsoidal particle in a
straight tube mimicking a capillary: as the flow starts, the
spherical particle moves to an equilibrium distance from the
wall and follows the original stream line parallelly to the
Fig. 2. Particles, rejected by the red blood cells, fast flowing in the
center of the vessel, tend to accumulate in close proximity to the walls
(as platelets) and more easily to leave larger vessels in favor of the
smaller. This would increase particle accumulation in the micro
capillary bed.
Fig. 3. The longitudinal (drag) force and the torque exerted over a
particle adhering to a cell layer under flow.
Fig. 4. The trajectory of neutrally buoyant spherical and ellipsoidal
particles in an idealized capillary (straight cylindrical tube) under
typical capillary hydrodynamic conditions (the ratio between the
spherical particle diameter and the tube diameter is 5; the ratio
between the minor axis of the ellipsoidal particle and the tube
diameter is 10 and the ellipsoidal particle has an aspect ratio of 2)
(32).
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blood vessel wall; whereas the ellipsoidal particle rotates and
translates downstream drifting laterally from one side to the
other of the capillary, ‘exploring’ the blood vessel walls. More
recently, in-vitro experiments have been conducted using
spherical, discoidal and quasi-hemispherical particles with the
same weight injected into a parallel plate flow chamber under
controlled hydrodynamic conditions (33). The experiments
have shown that discoidal particles tend to marginate more
than quasi-hemispherical and more than spherical particles in
a gravitational field (Fig. 5). Notably, these observations
neglect the interaction of the particles with blood cells, in
particular RBCs. However, this is a reasonable assumption as
long as the particles are sufficiently smaller than RBCs and
tend to accumulate within the cell-free layer.
Firm Adhesion
The particle moving in close proximity to the blood
vessels can interact both specifically and non-specifically with
the endothelial cells and adhere firmly to it, once suitable
conditions are met in terms of hydrodynamic shear stress at
the wall and, type and level of expression of receptor
molecules. From there, the particles can release their payload
towards the extravascular matrix or act as vascular contrast
agents in imaging applications.
Firm adhesion is ensured as long as the dislodging forces
(hydrodynamic forces and any other force acting to release
the particle from the target cell) are balanced by specific
ligand-receptor interactions and non-specific adhesion forces
arising at the cell/particle interface. The strength of adhesion
can be expressed in terms of an adhesion probability Pa,
defined as the probability of having at least one ligand-
receptor bond formed under the action of the dislodging
forces. Pa is affected by the shear stress at the blood vessel
wall μS, by the surface density of ligand molecules ml
distributed over the particle surface and of receptor mole-
cules mr expressed at the cell membrane, and by the size a
and shape (aspect ratio γ) of the particle (34). Interestingly,
for each particle shape, a characteristic size can be identified
for which the probability of adhesion has a maximum: for
small particles, the hydrodynamic forces are small but the
area of interaction at the particle/cell interface is also smaller
leading consequently to a small number of ligand-receptor
bonds involved which can not withstand even small dislodging
force; for large particles, the number of ligand-receptor bonds
that can be formed grows but the hydrodynamic forces grow
Fig. 5. The number of particles sedimenting on the bottom of a parallel plate flow chamber: the effect of different particle shapes (spherical
particle: d=1 μm; discoidal particle: d=1.5 μm and h=0.3 μm; quasi-hemispherical particle: d=1.6 μm).
Fig. 6. Controlling cell uptake by using particles with different shapes: ovoidal and spherical particles are more easily internalized compared to
elongated particles laying parallelly to the cell membrane.
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even more. The optimal size for adhesion, that is the size for
which Pa has a maximum, falls between these two limiting
conditions. As an example, when considering a capillary with
a shear stress at the wall of μS=1 Pa and a surface density of
receptors mr=100 μm
2, the optimal radius for a spherical
particle would be of about 500 nm with a total volume of
0.05 μm3, whereas the optimal volume for an oblate
spheroidal particle with an aspect ratio γ=2 would be more
than 50 times larger (3.5 μm3) (34).
For a spherical particle, a simple relationship has been
derived showing how the optimal radius aopt is proportional
to μS−0.72. Goetz and his group (35) ran in-vitro adhesion
experiments employing polystyrene particles with different
diameters, namely 5, 10, 15, and 20 μm, injected into a
parallel plate flow chamber and have determined
experimentally the variation of the critical shear stress μS as
a function of the particle radius a. A fitting of the
experimental data leads to the relation which indeed is not
too far from the theoretical prediction. For non-spherical
particles, an explicit expression for the optimal size/volume
can not be derived due to mathematical complexity, however
the authors have shown that as the aspect ratio of an oblate
spheroidal particle increases, the volume for which the
maximum strength of adhesion is reached increases too.
Control of Internalization
Once the particle has adhered to the target cell, it should
be internalized if the aim is to release drugs or therapeutic
agents within the cytosol or at the nuclear level (gene
delivery); or it should resist internalization if the target cell
is used just as a docking site (vascular targeting) from which
release second stages particles. The internalization rate is
affected by the geometry of the particle.
This has been clearly shown by a number of authors for
spherical particles, where the size (radius) not only affects the
internalization rate, the larger is the radius and the longer is
the time for cell uptake, but it also affects the internalization
mechanism (36–38). In a rough estimate, small particles
(<500 nm) are internalized by receptor mediated endocytosis,
a process requiring only a local modest rearrangement of the
cell cytoskeleton; large particles (>1 μm) are internalized
through a phagocytic process which conversely requires an
extensive rearrangement of the cell cytoskeleton with the
formation of protruding actin filaments; particles with an
intermediate size (>500 nm and <1 μm) are thought to be
internalized through a mixed mode. Chan’s group (39) has
observed, by using gold spherical particles ranging in size
from 10 to 100 nm, a maximum in the number of uptaken
Fig. 7. A sketch of the assembly of Au-phage constructs and non
spherical nano-porous silicon particles: the Au-phage construct
provides the selective recognition of biological targets without
altering the geometrical properties of the silicon particle.
Fig. 8. A SEM image of networks of direct-assembled Au-phage scaffolds covering nano-porous microfabricated silicon particles. The shape of
the silicon particle is preserved and the filamentous phage provides the exquisite targeting capability.
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particles for 50 nm spheres. The existance of a maximum was
already observed by Osaki et al. (40). Freund and colleagues
(41) developed a mathematical model for receptor-mediated
endocytosis based on an energetic analysis showing that a
threshold particle radius ath exists below which endocytosis
could never occur and, that an optimal particle radius aopt
exists, slightly larger than ath, for which internalization is
favored with the maximum internalization rate, thus confirm-
ing theoretically the above cited experimental observations.
This analysis was then generalized (30) to account for the
contribution of the surface physico-chemical properties that
may dramatically affect the internalization process changing
significantly both aopt and ath, as shown by Foged et al. (42).
More recently the effect of particle shape has been also
considered by Mitragotri and his collaborators (16) for
micrometer polystyrene particles phagocytosed by macro-
phages, and by Chan and his group (39) for gold nano-rods
internalized by HeLa cells. The first group has shown in-vitro
that the internalization of non-spherical particles is strongly
influenced by their orientation with respect to the cell
membrane. A characteristic angle Ω has been introduced
varying between 0 and 90°, with Ω tending to zero for slender
particles having their major axis aligned orthogonally to the
cell membrane and tending to 90° for slender particles with
their major axis parallel to the cell membrane. The angle Ω is
45° for a spherical particle. The rate of internalization was
shown to increase with an increase in Ω tending to zero (no
internalization) for angles larger than about 50°. At the
nanoscale, Chan and collaborators have observed that gold
nano-rods with large length-to-radius ratio (elongated) are
internalized in a smaller portion compared to spherical
particles with an equivalent characteristic size. The authors
noted that this could be attributed either to the different
curvature of the particles (spherical versus cylindrical) or to
the different amount of molecules adsorbed onto the particle
surface mediating the particle-cell interaction. More interest-
ingly, Chan and colleagues have also shown how the particle
geometry at the nanoscale can have an effect on the
biological activity of the cell (43).
A more recent theoretical model has been developed by
the authors for the receptor mediated endocytosis of non-
spherical particles (44) showing how elongated particles
laying parallelly to the cell membrane are less prone to
internalization compared to spherical particles or particles
laying normally to the cell membrane (Fig. 6). These results
clearly show how particle size and shape can be used to
control the internalization process effectively, and that
particles slightly deviating from the spherical shape are more
easily internalized compared to elongated particles deviating
severely from the classical spherical shape.
RATIONAL DESIGN OF PARTICULATE SYSTEMS
The performance of a particulate systems administered
at the systemic level is influenced by physiological and
biophysical properties, as the hydrodynamic conditions at
the site of adhesion and the surface density of receptor
molecules, and by particle properties that can be controlled
during the manufacturing process as the geometry (size and
shape) and the surface features (density of ligand molecules,
density and length of polymer chains, electrostatic charge).
Clearly, the number of possible combinations is extraordi-
narily large and thus requires a rational approach to the
selection of the best particle just as in engineering optimiza-
tion problems where the best solution has to be found within
all feasible solutions given specific constrains and objective
functions.
Recently, a mathematical model has been developed (45)
that allows to predict the adhesive and endocytotic perform-
ances of particulate systems based on three different catego-
ries of governing parameters: geometrical (radius of the
particle); biophysical (ligand-to-receptor surface density ratio;
non-specific interaction parameter; hydrodynamic force pa-
rameter) and biological (ligand-receptor binding affinity).
This finding has lead to the definition of design maps through
which the three different states of the particulate system can
be predicted: no adhesion at the blood vessel walls; firm
adhesion with no internalization by the endothelial cells; firm
adhesion and internalization.
These all emphasize the importance that both geometry
and surface physico-chemical properties have in the design of
particulate systems. In this respect, the integration of phage
display-based combinatorial tissue targeting and microfabri-
cated particulate systems is emerging as a powerful tool. It
has been now clearly established that the assembly of phage
and nanoparticles occurs spontaneously, without the need for
cross-liking, conjugation or phage genetic alterations, possibly
yielding a broad range of applications. For instance, biolog-
ically active networks of direct-assembled Au-phage scaffolds
have already shown highly favorable properties in vivo
(11,46,47). These are the result of the spontaneous self-
assembly of filamentous phages and 40 nm gold nano-
particles, and the adhesive and internalization properties of
this construct have been shown to be easily tunable by
changing the phage/particle ratio and the level of aggregation.
More recently, the Au-phage scaffolds have been com-
bined with non-spherical silicon particles (Figs. 7 and 8)
leading to a particulate system whit superior targeting
properties (filamentous phage) and with an exquisite control
on size and shape (microfabricated silicon particle).
CONCLUSIONS
The characterization of the endothelial biodiversity and
the precise control of size and shape in micro/nano-fabrica-
tion have promoted a paradigm shift in the systemic
administration of particulate systems for biomedical applica-
tions: both geometry and surface physico-chemical properties
contribute substantially to the optimal design of the particu-
late system.
Geometry affects the transport and biodistribution of the
particles, at the vascular level; the strength of adhesion and
the internalization rate at the cellular level. Geometry favors
particle accumulation in proximity of the blood vessels
(margination dynamics) to better sense endothelial wall
biodiversity. Geometry affects the strength of adhesion to
cells improving target specificity. Geometry influences the
rate of internalization discriminating between particles for
nuclear delivery (rapid internalization) and particles for
vascular targeting (no internalization).
In this respect, the integration of phage display-based
combinatorial tissue targeting and microfabricated particulate
241Intravascular Delivery of Particulate Systems
systems is emerging as a powerful tool: the filamentous phage
provide exquisite targeting while preserving the peculiar
geometry of the microfabricated particulate.
As with the ‘rational drug design’ introduced within the
pharmaceutical community decades ago (48), predictive
mathematical models, in-vitro assays and in-vivo testing need
to be integrated in one sole framework for the selection of
optimal particulate systems leading to what can be baptized
as the rational design of particulate systems.
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